EGFR and lung cancer: A systematic review of pharmacological interventions performed on GEMMs of lung cancer [23] suggest that with respect to the most clinically relevant mutations, such as those in EGFR [78] and ALK [79], GEMMs well recapitulated the features of human tumours in terms of response and resistance mechanisms.